Age limits Praluent is FDA-approved for use starting at age 8, while Repatha is approved for use starting at age 10
For instance, certain studies have indicated that glutathione levels are lower in individuals with chronic kidney disease, highlighting its potential importance in renal health
Untreated bowel obstruction or ileus may lead to intestinal ischemia, tissue damage, perforation, infection, sepsis, and the need for emergency surgical intervention
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O et al (2022) AGA clinical practice guideline on Pharmacological interventions for adults with obesity
These studies test investigative weight loss medications or new methods of administering them and aim to understand how they work in individuals from diverse backgrounds
Lilly also has an obesity pill in the final stage of development with a key trial slated to end in April